Stereotactic radiotherapy for metastatic kidney cancer patients on TKIs

This phase 2 study looked at the use of stereotactic radiotherapy to treat metastatic renal cell carcinoma (RCC) in patients where the cancer had spread and there were a small number of metastases. These patients were on a tyrosine kinase inhibitor as the first or second medicine for their cancer. The aim of the study […]

read more

Stereotactic radiotherapy for patients on TKIs

Stereotactic radiotherapy is a very precise method of radiotherapy that uses fewer doses of radiation than conventional radiotherapy. In this study of 37 patients with spread of their cancer (metastases) at a limited number of places in the body, the researchers looked at how stereotactic radiotherapy affected the outcomes of patients on tyrosine kinase inhibitors, […]

read more

Stereotactic radiotherapy with immunotherapy or targeted therapy for metastatic kidney cancer

This study looked at the safety and effectiveness of targeted therapies or immune checkpoint inhibitors (immunotherapy) in combination with stereotactic radiotherapy in patients with renal cell carcinoma (RCC). There were 53 patients in the study, of whom 32% were treated with immunotherapy and 68% targeted therapy. About a third of patients on targeted therapy paused […]

read more

Stereotactic radiosurgery for multiple kidney cancer brain metastases

A recent study published in Clinical Genitourinary Cancer¬†has shown that stereotactic radiosurgery (SRS) is effective for controlling renal cell carcinoma (RCC) brain metastases, although the effectiveness of SRS is not so good with larger metastatic tumours. In the study, more than half of the patients treated with SRS survived beyond a year, and there were […]

read more

ESMO 2018: Assessment of asymptomatic brain metastases in kidney cancer patients

The results of an analysis of renal cell carcinoma (RCC) patients with brain metastases that were not causing any symptoms (asymptomatic metastatses) from the phase 2 GETUG-AFU 26 (NIVOREN) clinical trial were presented at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich last week. The GETUG-AFU 26 (NIVOREN) trial looked at the […]

read more

Stereotactic body radiotherapy may improve control of localised kidney cancer

A recent study published in The Journal of Urology¬†this month suggests that stereotactic body radiotherapy (SBRT) may be a safe and effective therapeutic option that could control the growth of localised, small numbers of metastases (oligometastatic) in people with advanced renal cell carcinoma (RCC). Fifty-eight RCC patients, who had undergone surgery and had a maximum […]

read more

Stereotactic radiotherapy for metastatic kidney cancer

A paper published in the European Journal of Cancer earlier this month reports on the experience of six French hospitals with stereotactic radiotherapy (SRT) for metastatic renal cell carcinoma (RCC) between 2008 and 2015 . This retrospective study showed a 12-month local control rate of metastases of 82.9%. Twenty-five percent of patients with oligometastatic disease […]

read more
Showing all 7 results
  TOP